Orgenesis Common Stock vs Total Current Assets Analysis

ORGS Stock

USD 0.54 0.01 1.89%

Orgenesis financial indicator trend analysis is much more than just breaking down Orgenesis prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Orgenesis is a good investment. Please check the relationship between Orgenesis Common Stock and its Total Current Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.

Common Stock vs Total Current Assets

Common Stock vs Total Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Orgenesis Common Stock account and Total Current Assets. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Orgenesis' Common Stock and Total Current Assets is -0.4. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Orgenesis, assuming nothing else is changed. The correlation between historical values of Orgenesis' Common Stock and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Orgenesis are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Common Stock i.e., Orgenesis' Common Stock and Total Current Assets go up and down completely randomly.

Correlation Coefficient

-0.4

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most indicators from Orgenesis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Orgenesis current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.At this time, Orgenesis' Discontinued Operations is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 5.9 M in 2024, whereas Tax Provision is likely to drop (87.2 K) in 2024.

	2023	2024 (projected)
Reconciled Depreciation	1.7M	1.7M
Interest Income	31.5K	29.9K

Reconciled Depreciation Interest Income

Orgenesis fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Non Current Assets Total	Other Current Assets	Intangible Assets	Other Liab	Property Plant And Equipment Net	Non Currrent Assets Other	Other Assets	Net Receivables	Short Term Investments	Non Current Liabilities Total	Inventory
Total Assets		0.68	0.8	0.8	-0.04	-0.49	0.69	0.62	0.62	0.21	0.55	0.44	0.75	0.92	-0.36	0.79	0.5	0.18	0.02	0.68	0.82	0.44	0.6	0.65	0.58	0.49
Other Current Liab	0.68		0.77	0.38	0.52	-0.46	0.51	0.32	0.32	0.23	0.67	0.03	0.85	0.46	-0.34	0.58	0.23	0.18	0.14	0.49	0.46	0.13	0.22	0.76	0.76	0.83
Total Current Liabilities	0.8	0.77		0.46	0.16	-0.64	0.85	0.43	0.43	0.35	0.54	0.49	0.89	0.61	-0.2	0.74	0.51	0.2	0.25	0.48	0.5	0.37	0.35	0.87	0.64	0.45
Total Stockholder Equity	0.8	0.38	0.46		-0.3	-0.24	0.54	0.76	0.76	0.01	0.46	0.31	0.31	0.85	-0.32	0.53	0.16	0.11	-0.29	0.43	0.76	0.58	0.4	0.42	0.2	0.41
Net Debt	-0.04	0.52	0.16	-0.3		-0.26	-0.07	-0.49	-0.49	-0.28	0.47	-0.22	0.27	-0.24	0.03	-0.04	0.1	-0.13	0.07	0.12	-0.15	-0.01	0.12	0.27	0.27	0.3
Retained Earnings	-0.49	-0.46	-0.64	-0.24	-0.26		-0.76	-0.26	-0.26	0.13	-0.77	-0.81	-0.49	-0.52	0.34	-0.34	-0.8	0.27	0.17	-0.35	-0.47	-0.52	-0.5	-0.55	-0.29	-0.04
Accounts Payable	0.69	0.51	0.85	0.54	-0.07	-0.76		0.66	0.66	0.01	0.63	0.68	0.64	0.67	-0.14	0.53	0.56	0.0	0.03	0.31	0.45	0.48	0.25	0.73	0.38	0.18
Cash	0.62	0.32	0.43	0.76	-0.49	-0.26	0.66		1.0	0.03	0.41	0.27	0.36	0.76	-0.32	0.32	0.09	0.11	-0.08	0.17	0.52	0.27	0.01	0.39	0.27	0.35
Cash And Short Term Investments	0.62	0.32	0.43	0.76	-0.49	-0.26	0.66	1.0		0.03	0.41	0.27	0.36	0.76	-0.32	0.32	0.09	0.11	-0.08	0.17	0.52	0.27	0.01	0.39	0.27	0.35
Common Stock Total Equity	0.21	0.23	0.35	0.01	-0.28	0.13	0.01	0.03	0.03		-0.27	0.04	0.41	0.03	-0.27	0.36	0.0	0.31	0.39	0.04	0.25	-0.16	0.0	0.2	0.28	0.33
Common Stock Shares Outstanding	0.55	0.67	0.54	0.46	0.47	-0.77	0.63	0.41	0.41	-0.27		0.41	0.48	0.55	-0.39	0.16	0.45	-0.26	-0.22	0.19	0.51	0.51	0.35	0.59	0.27	0.42
Other Stockholder Equity	0.44	0.03	0.49	0.31	-0.22	-0.81	0.68	0.27	0.27	0.04	0.41		0.21	0.54	-0.19	0.33	0.85	-0.25	-0.19	0.24	0.53	0.56	0.61	0.34	-0.05	-0.32
Total Liab	0.75	0.85	0.89	0.31	0.27	-0.49	0.64	0.36	0.36	0.41	0.48	0.21		0.53	-0.28	0.7	0.36	0.27	0.41	0.51	0.45	0.16	0.23	0.74	0.86	0.64
Total Current Assets	0.92	0.46	0.61	0.85	-0.24	-0.52	0.67	0.76	0.76	0.03	0.55	0.54	0.53		-0.4	0.62	0.54	0.06	-0.13	0.59	0.85	0.47	0.63	0.5	0.39	0.3
Common Stock	-0.36	-0.34	-0.2	-0.32	0.03	0.34	-0.14	-0.32	-0.32	-0.27	-0.39	-0.19	-0.28	-0.4		-0.2	-0.15	0.22	0.22	-0.26	-0.41	-0.27	-0.19	-0.08	-0.28	-0.36
Non Current Assets Total	0.79	0.58	0.74	0.53	-0.04	-0.34	0.53	0.32	0.32	0.36	0.16	0.33	0.7	0.62	-0.2		0.39	0.24	0.15	0.88	0.57	0.29	0.47	0.53	0.74	0.41
Other Current Assets	0.5	0.23	0.51	0.16	0.1	-0.8	0.56	0.09	0.09	0.0	0.45	0.85	0.36	0.54	-0.15	0.39		-0.28	0.0	0.41	0.55	0.29	0.8	0.38	0.13	-0.25
Intangible Assets	0.18	0.18	0.2	0.11	-0.13	0.27	0.0	0.11	0.11	0.31	-0.26	-0.25	0.27	0.06	0.22	0.24	-0.28		0.23	0.11	-0.01	-0.11	-0.16	0.21	0.27	0.3
Other Liab	0.02	0.14	0.25	-0.29	0.07	0.17	0.03	-0.08	-0.08	0.39	-0.22	-0.19	0.41	-0.13	0.22	0.15	0.0	0.23		-0.05	-0.16	-0.18	-0.11	0.19	0.36	-0.01
Property Plant And Equipment Net	0.68	0.49	0.48	0.43	0.12	-0.35	0.31	0.17	0.17	0.04	0.19	0.24	0.51	0.59	-0.26	0.88	0.41	0.11	-0.05		0.54	0.24	0.58	0.32	0.71	0.32
Non Currrent Assets Other	0.82	0.46	0.5	0.76	-0.15	-0.47	0.45	0.52	0.52	0.25	0.51	0.53	0.45	0.85	-0.41	0.57	0.55	-0.01	-0.16	0.54		0.46	0.75	0.44	0.31	0.39
Other Assets	0.44	0.13	0.37	0.58	-0.01	-0.52	0.48	0.27	0.27	-0.16	0.51	0.56	0.16	0.47	-0.27	0.29	0.29	-0.11	-0.18	0.24	0.46		0.41	0.33	0.01	0.0
Net Receivables	0.6	0.22	0.35	0.4	0.12	-0.5	0.25	0.01	0.01	0.0	0.35	0.61	0.23	0.63	-0.19	0.47	0.8	-0.16	-0.11	0.58	0.75	0.41		0.27	0.09	-0.08
Short Term Investments	0.65	0.76	0.87	0.42	0.27	-0.55	0.73	0.39	0.39	0.2	0.59	0.34	0.74	0.5	-0.08	0.53	0.38	0.21	0.19	0.32	0.44	0.33	0.27		0.49	0.52
Non Current Liabilities Total	0.58	0.76	0.64	0.2	0.27	-0.29	0.38	0.27	0.27	0.28	0.27	-0.05	0.86	0.39	-0.28	0.74	0.13	0.27	0.36	0.71	0.31	0.01	0.09	0.49		0.67
Inventory	0.49	0.83	0.45	0.41	0.3	-0.04	0.18	0.35	0.35	0.33	0.42	-0.32	0.64	0.3	-0.36	0.41	-0.25	0.3	-0.01	0.32	0.39	0.0	-0.08	0.52	0.67

Click cells to compare fundamentals

Orgenesis Account Relationship Matchups

Orgenesis fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	73.9M	77.7M	59.8M	90.9M	14.6M	38.8M
Other Current Liab	6.8M	2.3M	2.4M	4.7M	4.1M	7.1M
Total Current Liabilities	17.2M	16.3M	15.4M	15.9M	16.4M	11.9M
Total Stockholder Equity	26.1M	52.6M	38.5M	27.6M	(21.0M)	27.4M
Net Debt	(32.0M)	6.4M	15.0M	21.8M	25.1M	26.3M
Retained Earnings	(65.2M)	(88.3M)	(106.4M)	(121.3M)	(176.6M)	(68.4M)
Accounts Payable	4.6M	8.6M	5.2M	4.4M	6.6M	3.7M
Cash	14.6M	44.9M	5.5M	5.3M	837K	15.3M
Cash And Short Term Investments	14.6M	44.9M	5.5M	5.3M	837K	15.3M
Common Stock Shares Outstanding	21.3M	24.3M	25.1M	29.0M	33.4M	35.0M
Liabilities And Stockholders Equity	77.7M	59.8M	90.9M	14.6M	16.7M	15.9M
Other Stockholder Equity	669K	140.1M	144.7M	149.1M	155.6M	635.6K
Total Liab	47.8M	25.0M	21.2M	31.7M	35.5M	25.6M
Total Current Assets	28.1M	50.1M	25.8M	46.3M	4.1M	15.1M
Non Current Assets Total	27.6M	34.1M	44.6M	10.5M	12.0M	11.4M
Other Current Assets	387K	1.7M	1.7M	4.7M	3.1M	367.7K
Intangible Assets	16.6M	13.0M	11.8M	9.7M	7.4M	9.9M
Other Liab	2.2M	387K	389K	578K	2.0M	2.5M
Property Plant And Equipment Net	4.5M	11.3M	25.1M	1.8M	2.1M	2.0M
Non Currrent Assets Other	440K	821K	805K	1.4M	18K	708.5K
Other Assets	1.3M	1.5M	2.8M	8.6M	1.7M	1.8M
Net Receivables	3.2M	3.3M	18.5M	39.8M	2.6M	3.1M
Non Current Liabilities Total	8.7M	5.8M	15.7M	19.1M	22.0M	16.6M
Inventory	1.7M	185K	118K	120K	34K	1.7M
Property Plant And Equipment Gross	12.5M	4.5M	11.3M	29.1M	2.4M	10.1M
Property Plant Equipment	11.9M	12.5M	4.3M	5.1M	14.3M	15.0M
Short Long Term Debt Total	4.8M	12.9M	11.8M	20.3M	22.6M	4.5M
Accumulated Other Comprehensive Income	1M	748K	207K	(270K)	65K	1.1M
Short Term Debt	753K	4.6M	6.4M	5.1M	3.6M	715.4K
Net Tangible Assets	(5.8M)	30.8M	18.3M	9.7M	(6.7M)	(6.3M)
Current Deferred Revenue	751K	1.3M	1.6M	2.2M	2.5M	3.6M
Short Long Term Debt	753K	4.1M	5.9M	4.5M	3.3M	715.4K
Long Term Debt	2.8M	7.3M	4.9M	13.3M	19.0M	2.7M
Good Will	15.3M	8.7M	8.4M	8.2M	1.2M	8.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Orgenesis is a strong investment it is important to analyze Orgenesis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Orgenesis' future performance. For an informed investment choice regarding Orgenesis Stock, refer to the following important reports:

How To Invest In Orgenesis

Details

Is Orgenesis Stock a good investment?

Details

What is Orgenesis' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.

Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Orgenesis Stock analysis

When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.

	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon

Is Orgenesis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orgenesis. If investors know Orgenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orgenesis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.91)

Revenue Per Share

0.018

Quarterly Revenue Growth

(0.99)

Return On Assets

(0.62)

Return On Equity

(3.39)

The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Orgenesis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Orgenesis Common Stock vs Total Current Assets Analysis

Common Stock vs Total Current Assets

Common Stock vs Total Current Assets Correlation Analysis

Correlation Coefficient

Common Stock

Total Current Assets

Orgenesis fundamental ratios Correlations

Orgenesis Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Orgenesis fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Orgenesis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.92	Total Assets
Total Liab	+ 0.89	Total Current Liabilities
Property Plant And Equipment Net	+ 0.88	Non Current Assets Total
Short Term Investments	+ 0.87	Total Current Liabilities
Non Current Liabilities Total	+ 0.86	Total Liab

Other Stockholder Equity	- 0.81	Retained Earnings
Other Current Assets	- 0.8	Retained Earnings
Common Stock Shares Outstanding	- 0.77	Retained Earnings
Accounts Payable	- 0.76	Retained Earnings
Retained Earnings	- 0.64	Total Current Liabilities
Short Term Investments	- 0.55	Retained Earnings